REGN - REGENERON PHARMACEUTICALS, INC.

QQQ $ 462.76 $ -0.41 (-0.09 %)

DIA $ 388.38 $ -0.84 (-0.22 %)

SPY $ 533.54 $ -0.65 (-0.12 %)

TLT $ 91.51 $ -1.71 (-1.83 %)

GLD $ 211.60 $ -7.83 (-3.57 %)

Previous Close

$ 1002.95

Open

$ 998.23

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 995.62 - $ 1,007.58

52 Week Range

$ 684.81 - $ 1,016.00

Volume

250,100

Average Volume

Market Cap

115.44B

Beta (5Y Monthly)

$ 0.53

PE Ratio (TTM)

$ 29.92

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-02-2024	03-31-2024	10-Q
2	02-05-2024	12-31-2023	10-K
3	11-02-2023	09-30-2023	10-Q
4	08-03-2023	06-30-2023	10-Q
5	05-04-2023	03-31-2023	10-Q
6	02-06-2023	12-31-2022	10-K
7	11-03-2022	09-30-2022	10-Q
8	08-03-2022	06-30-2022	10-Q
9	05-04-2022	03-31-2022	10-Q
10	02-07-2022	12-31-2021	10-K
11	11-04-2021	09-30-2021	10-Q
12	08-05-2021	06-30-2021	10-Q
13	05-06-2021	03-31-2021	10-Q
14	02-08-2021	12-31-2020	10-K
15	11-05-2020	09-30-2020	10-Q
16	08-05-2020	06-30-2020	10-Q
17	05-05-2020	03-31-2020	10-Q
18	02-07-2020	12-31-2019	10-K
19	11-05-2019	09-30-2019	10-Q
20	08-06-2019	06-30-2019	10-Q
21	05-07-2019	03-31-2019	10-Q
22	02-07-2019	12-31-2018	10-K
23	11-06-2018	09-30-2018	10-Q
24	08-02-2018	06-30-2018	10-Q
25	05-03-2018	03-31-2018	10-Q
26	02-08-2018	12-31-2017	10-K
27	11-08-2017	09-30-2017	10-Q
28	08-03-2017	06-30-2017	10-Q
29	05-04-2017	03-31-2017	10-Q
30	02-09-2017	12-31-2016	10-K
31	11-04-2016	09-30-2016	10-Q
32	08-04-2016	06-30-2016	10-Q
33	05-05-2016	03-31-2016	10-Q
34	02-11-2016	12-31-2015	10-K
35	11-04-2015	09-30-2015	10-Q
36	08-04-2015	06-30-2015	10-Q
37	05-07-2015	03-31-2015	10-Q
38	02-12-2015	12-31-2014	10-K
39	11-04-2014	09-30-2014	10-Q
40	08-05-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

goldman-sachs-optimistic-about-regenxbios-gene-therapy-pipeline-sees-over-160-upside

Goldman Sachs Optimistic About Regenxbio's...
06/07/2024 18:30:54

Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.

What's Going On With FibroGen Stock Tuesday?
06/04/2024 18:27:03

FibroGen Inc (NASDAQ:FGEN) shares are trading higher Tuesday morning after the company said the FDA cleared its Investigational...

Competitor Analysis: Evaluating Regeneron ...
06/04/2024 15:00:55

Navigating 14 Analyst Ratings For Regenero...
06/04/2024 14:01:20

RBC Capital Maintains Outperform on Regene...
06/04/2024 13:53:13

RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and raises the price ...

fibrogen-stock-is-surging-after-the-bell-whats-going-on

FibroGen Stock Is Surging After The Bell: ...
06/03/2024 20:48:42

FibroGen shares are moving higher in Monday's after-hours session after the company announced the FDA cleared its Investiga...

FibroGen Inks Clinical Trial Supply Agreem...
06/03/2024 20:09:25

FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combi...

heres-how-much-100-invested-in-regeneron-pharmaceuticals-10-years-ago-would-be-worth-today

Here's How Much $100 Invested In Regeneron...
06/03/2024 18:00:24

fda-extends-review-deadline-for-regeneronsanofis-dupixent-for-smokers-lungs-disease

FDA Extends Review Deadline For Regeneron/...
05/31/2024 13:23:50

The FDA extends the target action date for reviewing Dupixent as an add-on treatment for uncontrolled COPD to September 27, 202...

Sanofi And Regeneron Pharmaceuticals' Dupi...
05/31/2024 06:34:29

Dupixent recommended for EU approval by the CHMP to treat patients with COPD Recommendation for adults with uncontrolled COP...

FDA Extends Priority Review Deadline For R...
05/31/2024 05:55:36

The US Food and Drug Administration (FDA) has extended by three months the target action date of its priority review of the sup...

whats-going-on-with-biohaven-stock-wednesday

What's Going On With Biohaven Stock Wednes...
05/29/2024 16:03:45

The company announced it dosed a patient with a new possible treatment for certain cancers, showcased positive data from two di...

after-unitedhealth-cyberattack-drug-distributor-cencora-notifies-americans-health-information-stolen-in-data-breach-in-february

After UnitedHealth Cyberattack, Drug Distr...
05/24/2024 16:00:24

Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnose...

regn---analyzing-regeneron-pharmaceuticalss-short-interest

(REGN) - Analyzing Regeneron Pharmaceutica...
05/20/2024 19:15:23

Regeneron Pharmaceuticals And Sanofi Prese...
05/20/2024 18:17:57

NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% ...

Insights Into Regeneron Pharmaceuticals's ...
05/17/2024 15:00:51

heres-how-much-you-would-have-made-owning-regeneron-pharmaceuticals-stock-in-the-last-10-years

Here's How Much You Would Have Made Owning...
05/14/2024 14:30:25

Evercore ISI Group Initiates Coverage On R...
05/14/2024 09:13:39

Evercore ISI Group analyst Cory Kasimov initiates coverage on Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform rati...

Regeneron Pharmaceuticals And Sanof's Dupi...
05/13/2024 07:00:51

If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately c...

Regeneron Announces Prelim. Data In An ASG...
05/08/2024 10:03:41

Notes From The Street: 'FLASHBACK....Oil G...
01/13/2015 13:20:41